The firm reported 29 percent growth in its overall testing revenues, driven mainly by higher reproductive test volume and higher per-test revenue.
CombiMatrix said the move will increase access to the test in the state for women experiencing recurrent pregnancy loss.
The company's testing was successful in more than 90 percent of cases over almost four years, and detected a wide variety of abnormalities.
The company reported an 18 percent increase in the number of reproductive health tests completed during the quarter.
The company feels it could be an attractive target for mergers, but is also keeping an eye out for IP acquisition options of its own.
The company said its revenue increase was driven by gains in test volume, particularly in miscarriage analysis and preimplantation genetic screening for couples undergoing IVF.
The research project, led by Kathy Niakan of the Francis Crick Institute, will involve editing several genes thought to be important to embryo development.
The UK Human Fertilisation & Embryology Authority is to consider an application submitted by researchers seeking to perform gene editing on human embryos.
Scientists from The Francis Crick Institute have applied to UK regulators to use CRISPR/Cas9 genome editing in an upcoming study of miscarriage.
Chromsomal array testing had a higher diagnostic yield in the study than standard procedures, and could have value as a first step before referring patients to further tests.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.